Novartis (skin cancer drug)

Novartis (skin cancer drug) Overview

Status Acquired/​Merged
Latest Deal Type Asset Purch.
Financing Rounds 1

Novartis (skin cancer drug) General Information

Description

The asset is a skin cancer drug Odomzo of Novartis. The drug is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Primary Office
  • Basel
  • Switzerland
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis (skin cancer drug) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis (skin cancer drug)‘s full profile, request access.

Request a free trial

Novartis (skin cancer drug) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis (skin cancer drug)‘s full profile, request access.

Request a free trial